Tagged: physician-scientist
11 results
Senan Ebrahim
Senan Ebrahim is the founder and CEO of Delfina, a San Francisco digital health company using AI and data science to improve pregnancy care and close gaps in maternal health. A physician-scientist with an MD and a PhD in computational neuroscience from Harvard, he founded Delfina after witnessing a preventable stillbirth during medical training. He earlier founded Hikma Health, a nonprofit building free health-data tools for refugee and low-income patients. Delfina raised a $17M Series A in early 2025 led by U.S. Venture Partners.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.
Maria Artunduaga
Maria Artunduaga is a Colombian-born physician-scientist, inventor and founder and CEO of Samay (formerly Respira Labs), a Mountain View medtech startup building a wearable plus AI platform that uses patented acoustic resonance to monitor lung function at home. She walked away from a plastic surgery residency at the University of Chicago after losing her grandmother Sylvia, taught herself engineering, and turned a kitchen-table idea into a company that has won the world's most competitive medtech accelerator and landed her on Inc.'s 2025 Female Founders list. She holds an MD, an MPH and an MTM, has collected dozens of prizes, six issued patents, and publications in Nature, NEJM and PNAS.
Jacob Donoghue
Jacob Donoghue is a physician-scientist and the co-founder and CEO of Beacon Biosignals, a Boston company applying machine learning to EEG brain data to build neurobiomarkers for psychiatric, neurological, and sleep disorders. Trained with an MD from Harvard Medical School and a PhD in neuroscience from MIT, he started Beacon in 2019 on the bet that decades of overlooked brainwave recordings could be turned into a precision-medicine engine for drug development and diagnosis. Under his leadership the company has raised over $116M, secured FDA clearance for a wearable EEG headband, acquired home sleep-testing firm CleveMed, and partnered with more than half of the world's top ten biopharma companies.
Michelle Longmire
Dr. Michelle Longmire is the co-founder and CEO of Medable, the leading platform for agentic AI in clinical development. A Stanford-trained physician-scientist who grew up in a Los Alamos nuclear-research family, she pivoted from dermatology to founding Medable in 2015 after hitting enrollment walls in her own clinical research. Under her leadership, Medable has raised over $500 million in venture capital, deployed its platform in roughly 400 trials across 70 countries in 120 languages, and served more than one million patients globally - transforming how the world runs clinical trials.
Eric Green
Eric Green is the Founder and CEO of Trace Neuroscience, a South San Francisco biotech company racing to develop the first effective ASO therapy for ALS. A Harvard-and-Stanford-trained physician-scientist with a background in cardiology, Green co-founded iLab Solutions (acquired by Agilent), Respira Design (Stanford $50K Challenge winner), and Maze Therapeutics before launching Trace with a $101 million Series A in November 2024. Trace's lead program targets UNC13A - a protein lost in ALS patients - using an antisense oligonucleotide designed to restore healthy nerve-muscle communication. With clinical trials targeting early 2026, Green is betting human genetics can do for ALS what it did for heart failure.
Jorge Dimartino
Jorge F. DiMartino, M.D., Ph.D., is Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium, a San Diego-based biotech pioneering targeted protein degradation. A physician-scientist trained in genetics, immunology, and pediatric oncology across UC Berkeley, Cornell, UC San Diego, and Stanford, DiMartino has spent over two decades advancing cancer drugs from bench to bedside. His fingerprints are on three now-marketed therapies: vismodegib, venetoclax, and enasidenib - each a breakthrough in its own right. At Plexium, he oversees clinical programs targeting SMARCA2, IKZF2, CDK2, and CRAF using the company's DELTA Discovery platform, a novel approach to degrading proteins previously considered undruggable.
Josh Lehrer
Josh Lehrer is a physician-scientist and biotech executive serving as CEO of Marea Therapeutics, a clinical-stage company harnessing human genetics to develop first-in-class medicines for cardiometabolic diseases. A cardiologist by training with degrees from Harvard, Cambridge, and UCSF, Lehrer brings over two decades of drug development experience spanning Genentech, Global Blood Therapeutics (where he oversaw the FDA approval of Oxbryta for sickle cell disease), and Graphite Bio. At Marea, he has led the company from a Third Rock Ventures incubation to a $190 million-funded enterprise with two clinical-stage programs showing strong early efficacy data, including a 53% reduction in remnant cholesterol with MAR001 published in The Lancet.
Pavan Cheruvu
Dr. Pavan K. Cheruvu is the President and CEO of Bitterroot Bio, a Palo Alto-based biotech pioneering the field of cardio-immunology — the intersection of the immune system and cardiovascular disease. A Rhodes Scholar, board-certified cardiologist, and physician-scientist who trained at Duke, Oxford, Harvard/MIT, Johns Hopkins, and UCSF, Cheruvu is guiding Bitterroot Bio's lead program BRB-002 — a first-in-class CD47-targeting therapy for atherosclerosis — through clinical development after a landmark $145M Series A in 2023 and positive Phase 1 results in 2025.
Ron Alfa
Ron Alfa is Co-Founder and CEO of Noetik, an AI-native biotech building foundation models trained on one of the world's largest collections of multimodal human tumor data. A physician-scientist with an MD-PhD from Stanford and an MA in the History of Medicine from UCL, Alfa spent six years at Recursion Pharmaceuticals rising to SVP Head of Research before co-founding Noetik in 2023. The company's OCTO-VC virtual cell models and TARIO-2 autoregressive transformer are designed to predict which cancer patients will respond to which therapies - attacking the 95% failure rate of cancer clinical trials from the data side rather than the pharmacology side. In January 2026, Noetik signed a landmark $50M licensing deal with GSK, one of the first large-scale transactions to monetize a biological foundation model as a scalable enterprise asset.
Tom Cahill
Thomas J. Cahill, MD, PhD is the founder and managing partner of Newpath Partners, a Boston-based life sciences venture firm he built from the ground up to translate breakthrough academic science into medicines. A structural biologist trained under two Nobel laureates, Cahill has co-founded more than a dozen biotech companies — including Prime Medicine, Chroma Medicine, and Autobahn Therapeutics — and became one of the pandemic's most consequential behind-the-scenes operators when he assembled Scientists to Stop COVID-19, a coalition that fed curated research directly to the White House and helped redirect Regeneron's manufacturing to Dublin.